Group 1 - The core viewpoint of the article highlights the significant stock price increase of Kangchen Pharmaceutical, which rose over 7% and reached a new high of 14.59 HKD since its listing [1] - The company reported a revenue of 1.569 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 23.7% [1] - The net profit attributable to equity shareholders was 498 million RMB, reflecting a year-on-year growth of 24.6% [1] Group 2 - Basic earnings per share were reported at 0.59 RMB, with an interim dividend proposed at 0.33 HKD per share, up from 0.30 HKD in the same period last year [1] - The sales of nephrology product series grew approximately 28.0% compared to the same period last year, with the flagship product, Uremic Clear Granules, maintaining its market leadership [1] - The sales of the women's and children's product series increased by about 17.5% year-on-year, becoming the second largest revenue contributor for the company [1]
康臣药业午后涨超7%创新高 上半年纯利同比增长24.6% 中期息0.33港元